Oxurion to Participate in Upcoming Conferences

Advertisement

Leuven, BELGIUM, Boston, MA, US June 1, 2023 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that the company will participate in three conferences in June:

Knowledge for Growth 2023 Antwerp
June 1, 2023
Flanders Meeting & Convention Center Antwerp
Michael Dillen, Chief Business Officer, will be available for meetings.

BIO International 2023
June 5-8, 2023
Boston Convention and Exhibition Center 
Tom Graney, CEO, will be available for meetings.

Advertisement

Clinical Trials at the Summit
June 10, 2023
Pendry Park City, Park City, UT
Tom Graney, CEO, will be available for meetings.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
[email protected]

 

Michael Dillen
Chief Business Officer
Tel: +32 16 75 13 10
[email protected]

 

 

US
Conway Communications
Mary T. Conway
m[email protected]

 

US
ICR Westwicke
Christopher Brinzey
Tel: +1 617 835 9304
[email protected]

 

Attachment

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.